Related Experiment Video
Updated: May 26, 2026
09:16
Detection of a CDH1 Rare Transcript Variant in Fresh-frozen Gastric Cancer Tissues by Chip-based Digital PCR
Published on: February 5, 2018
Programmed cell death 6 (PDCD6) as a prognostic marker for gastric cancers
Jung Hwan Yoon1, Yoo Jin Choi, Sung Geun Kim
1Department of Pathology, College of Medicine, The Catholic University of Korea, 505 Banpo-dong, Seocho-gu, Seoul, 137-701, Korea.
Summary
Programmed cell death 6 (PDCD6) is often increased in gastric cancers and linked to survival rates. Wild-type PDCD6 inhibits cancer cell viability, suggesting its potential as a prognostic biomarker.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Programmed cell death 6 (PDCD6) is implicated in apoptosis and tumorigenesis.
- The role of PDCD6 in gastric cancer development and progression requires further investigation.
Purpose of the Study:
- To investigate the contribution of PDCD6 to gastric cancer.
- To evaluate PDCD6 as a prognostic biomarker in advanced gastric cancer.
Main Methods:
- Immunohistochemistry to assess PDCD6 protein expression in 169 gastric cancer specimens.
- Analysis of PDCD6 mutations, methylation, DNA copy number, and mRNA transcripts.
- Functional studies using wild-type and mutant PDCD6 transfected cell lines (AGS and HEK293T).
Main Results:
- Increased PDCD6 expression observed in 73.4% of gastric cancer specimens.
- Altered PDCD6 expression significantly correlated with survival rates (P = 0.0069).
- Wild-type PDCD6 induced cell death and inhibited viability; mutant-type PDCD6 showed reduced tumor suppressor activity. Synergistic effect with 5-FU observed.
Conclusions:
- PDCD6 is frequently overexpressed in gastric cancer and serves as a significant prognostic biomarker.
- PDCD6 exhibits tumor suppressor functions through the induction of apoptosis and inhibition of cell viability.
- These findings highlight PDCD6's critical role in gastric cancer pathogenesis and its potential therapeutic implications.
